Recently, Zheyuan Technology, a trailblazer in the AI4S (AI for Science) domain, proudly announced the successful closure of its Series A1 funding round, raising over a hundred million yuan. This strategic investment was spearheaded by China Science & Merchants Capital Investment, with significant contributions from Zeyuan Fund and WiseMed. The influx of capital will be strategically allocated to propel the development of core drug pipelines, fortify patent protection, and enhance platform capabilities, with the overarching goal of establishing an "Innovation Hub for Drug Intellectual Property."

Since its inception in 2015, Zheyuan Technology has embraced an innovative model that harmonizes "AI4S + Diseases." Its proprietary computational medicine platform is dedicated to "deciphering diseases" and has achieved three landmark breakthroughs. The cutting-edge "Digital Twin of Life Functions" technology has paved the way for groundbreaking applications in "virtual clinical trials," which have undergone rigorous clinical validation.

At present, Zheyuan Technology boasts a plethora of accomplishments. The lead investor is convinced that the company's computational medicine platform boasts formidable technical barriers, while the co-investors express confidence in its prowess in IP innovation. The founder of Zheyuan Technology articulated that this funding round presents a golden opportunity to refine their business model and catalyze the transformation of pharmaceutical R&D towards engineered mass production.